At the news
? BULLISHIMPACT 6/10 COURT-RULING filed Mar 3, 2026 at 19:00 ET
The District Court for the Eastern District of Pennsylvania granted GSK's motion to dismiss a securities fraud class action with prejudice, ruling the claims were time-barred by the two-year statute of limitations. The court found that reasonably diligent plaintiffs would have discovered the factual basis (concealment of Zantac's NDMA risks) from publicly available MDL complaints, expert reports, court opinions, and news articles well before February 4, 2023. This dismissal removes a material litigation overhang for GSK, though the company still faces ongoing Zantac product liability exposure.
- Court granted GSK's motion to dismiss securities fraud class action with prejudice on statute of limitations grounds
- Court held that reasonably diligent plaintiffs would have discovered the facts underlying the claims before February 4, 2023
- Key public records cited: MDL complaints (Feb 2021), state court complaints (Aug 2021, Aug 2022), expert reports (Aug 2022), MDL Daubert opinion (Dec 6, 2022), unsealed Tanner Study (Dec 30, 2022)
- The case was filed on February 4, 2025, over 2 years after the facts were publicly discoverable
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access